Table 2 Risk of herpes zoster on rheumatoid arthritis patients during first bDMARD or tsDMARD use

Etanercept (n=2638)

460 (17.2)

10,593

43.4

2.5 (1.0–4.2)

Reference

1.19 (0.94–1.51)

0.146

Infliximab (n=1288)

238 (18.1)

4474

53.2

2.1 (0.9–3.7)

1.14 (0.95–1.36)

0.156

1.36 (1.06–1.74)

0.017

Adalimumab (n=3176)

526 (16.3)

11,749

44.8

2.1 (0.9–3.7)

1.09 (0.94–1.25)

0.273

1.29 (1.02–1.64)

0.032

Golimumab (n=1189)

130 (10.9)

2234

58.2

1.6 (0.8–2.8)

0.89 (0.69–1.14)

0.358

1.06 (0.79–1.42)

0.692

Tocilizumab (n=1359)

134 (9.7)

2619

51.2

1.2 (0.5–2.1)

0.74 (0.58–0.94)

0.013

0.88 (0.67–1.16)

0.369

Rituximab (n=65)

17 (25.4)

328

51.8

2.6 (1.5–5.0)

1.01 (0.52–1.97)

0.970

1.21 (0.60–2.41)

0.593

Tofacitinib (n=687)

48 (6.8)

478

100.4

0.5 (0.2–0.9)

2.06 (1.38–3.08)

<0.001

2.46 (1.61–3.76)

<0.001

Abatacept (n=1134)

133 (11.5)

2227

59.7

1.5 (0.6–2.6)

0.84 (0.66–1.06)

0.146

Reference